Key points are not available for this paper at this time.
This is the largest genomic characterization of clinically annotated rhabdomyosarcoma tumors to date and provides prognostic genetic features that refine risk stratification and will be incorporated into prospective trials.
Shern et al. (Thu,) studied this question.